The first 2 placebo-controlled trials (SAVOR-TIMI 53 and EXAMINE) involving the dipeptidyl peptidase (DPP)-4 inhibitors saxagliptin and alogliptin, respectively, both reported a neutral effect on a composite of CV death (including fatal stroke and fatal myocardial infarction [MI]), non-fatal MI, and non-fatal stroke (3P-MACE) [12,13]. The gene discussed is DPP4; the disease is Stroke.